Skip to content

Study · Non-randomized trial · 2016

4 results

Teriparatide and denosumab combination therapy and skeletal metabolism.

Idolazzi L, Rossini M, Viapiana O, Braga V, Fassio A, Benini C, Kunnathully V, Adami S, Gatti D

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA1 Jun 2016Cited by 30 (Europe PMC)

PMID27250971 (opens in a new tab)DOI10.1007/s00198-016-3647-y (opens in a new tab)PepBankPUB-27250971
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialMechanism

    In women with severe postmenopausal osteoporosis, bone turnover markers increased during teriparatide monotherapy.

    In plain wordsIn women with osteoporosis, bone turnover markers increased during teriparatide treatment alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone turnover markers
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the groups treated only with TPTD or with denosumab, bone turnover markers increased and decreased, respectively.
    1 context sentence
    Summary · context
    Fifty-nine women over 65 years old with severe postmenopausal osteoporosis (evidence of at least two moderate-severe vertebral fractures) were enrolled in the study.
  2. 02HumanNon-randomized trialMechanism

    In women with severe postmenopausal osteoporosis, DKK1 increased significantly later during teriparatide monotherapy.

    In plain wordsIn women with osteoporosis, DKK1 increased later during teriparatide treatment alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseDKK1
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In TPTD group, a later significant increase in DKK1 was observed, while in denosumab group, a progressive increase in SOST was associated with a progressive significant decrease in DKK1.
    1 context sentence
    Summary · context
    Fifty-nine women over 65 years old with severe postmenopausal osteoporosis (evidence of at least two moderate-severe vertebral fractures) were enrolled in the study.

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 03HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialMechanism

    In women with severe osteoporosis, CTX increased after teriparatide was added to denosumab treatment.

    In plain wordsIn women with osteoporosis, CTX increased after teriparatide was added to denosumab.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCTX after teriparatide addition
    Study

    n: not reported in source

    Comparator
    Start of teriparatide addition to denosumab
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    In the group treated first with denosumab and in which TPTD was added 3 months later, both CTX and P1NP increased 3 months after the beginning of TPTD.
    1 context sentence
    Summary · context
    Fifty-nine women over 65 years old with severe postmenopausal osteoporosis (evidence of at least two moderate-severe vertebral fractures) were enrolled in the study.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 04HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialMechanism

    In women with severe osteoporosis, P1NP increased after teriparatide was added to denosumab treatment.

    In plain wordsIn women with osteoporosis, P1NP increased after teriparatide was added to denosumab.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseP1NP after teriparatide addition
    Study

    n: not reported in source

    Comparator
    Start of teriparatide addition to denosumab
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    In the group treated first with denosumab and in which TPTD was added 3 months later, both CTX and P1NP increased 3 months after the beginning of TPTD.
    1 context sentence
    Summary · context
    Fifty-nine women over 65 years old with severe postmenopausal osteoporosis (evidence of at least two moderate-severe vertebral fractures) were enrolled in the study.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.